Literature DB >> 31353396

Unique miRNA profiling of squamous cell carcinoma arising from ovarian mature teratoma: comprehensive miRNA sequence analysis of its molecular background.

Kosuke Yoshida1,2, Akira Yokoi1,3, Takumi Kagawa2, Shingo Oda2, Satomi Hattori1, Satoshi Tamauchi1, Yoshiki Ikeda1, Nobuhisa Yoshikawa1, Kimihiro Nishino1, Fumi Utsumi4, Kaoru Niimi1, Shiro Suzuki1, Kiyosumi Shibata4, Hiroaki Kajiyama1, Tsuyoshi Yokoi2, Fumitaka Kikkawa1.   

Abstract

Owing to its rarity, the carcinogenesis and molecular biological characteristics of squamous cell carcinoma arising from mature teratoma remain unclear. This study aims to elucidate the molecular background of malignant transformation from the aspects of microRNA (miRNA) profiling. We examined 7 patients with squamous cell carcinoma and 20 patients with mature teratoma and extracted their total RNA from formalin-fixed paraffin-embedded tissues. Then we prepared small RNA libraries and performed comprehensive miRNA sequencing. Heatmap and principal component analysis revealed markedly different miRNA profiling in cancer, normal ovarian and mature teratoma tissues. Then we narrowed down cancer-related miRNAs, comparing paired-cancer and normal ovaries. Comparisons of cancer and mature teratoma identified two markedly upregulated miRNAs (miR-151a-3p and miR-378a-3p) and two markedly downregulated miRNAs (miR-26a-5p and miR-99a-5p). In addition, these findings were validated in fresh cancer tissues of patient-derived xenograft (PDX) models. Moreover, several miRNAs, including miR-151a-3p and miR-378a-3p, were elevated in the murine plasma when tumor tissues were enlarged although miR-26a-5p and miR-99a-5p were not elucidated in the murine plasma. Finally, we performed target prediction and functional annotation analysis in silico and indicated that targets genes of these miRNAs markedly correlated with cancer-related pathways, including 'pathway in cancer' and 'cell cycle'. In conclusion, this is the first study on miRNA sequencing for squamous cell carcinoma arising from mature teratoma. The study identified four cancer-related miRNAs that were considered to be related to the feature of malignant transformation. Moreover, miRNAs circulating in the murine plasma of the PDX model could be novel diagnostic biomarkers.
© The Author(s) 2019. Published by Oxford University Press.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31353396     DOI: 10.1093/carcin/bgz135

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  5 in total

1.  30-Year Experience With 22 Cases of Malignant Transformation Arising From Ovarian Mature Cystic Teratoma: A Rare Disease.

Authors:  Yan Li; Meng Qin; Ying Shan; Huan-Wen Wu; Xiao-Ding Liu; Jie Yin; Yu Gu; Wei Wang; Yong-Xue Wang; Jia-Yu Chen; Li Ma; Ying Jin; Ling-Ya Pan
Journal:  Front Oncol       Date:  2022-05-09       Impact factor: 5.738

2.  Expression of the chrXq27.3 miRNA cluster in recurrent ovarian clear cell carcinoma and its impact on cisplatin resistance.

Authors:  Kosuke Yoshida; Akira Yokoi; Mai Sugiyama; Shingo Oda; Kazuhisa Kitami; Satoshi Tamauchi; Yoshiki Ikeda; Nobuhisa Yoshikawa; Kimihiro Nishino; Kaoru Niimi; Shiro Suzuki; Fumitaka Kikkawa; Tsuyoshi Yokoi; Hiroaki Kajiyama
Journal:  Oncogene       Date:  2021-01-08       Impact factor: 9.867

3.  Extracellular microRNA profiling for prognostic prediction in patients with high-grade serous ovarian carcinoma.

Authors:  Kosuke Yoshida; Akira Yokoi; Juntaro Matsuzaki; Tomoyasu Kato; Takahiro Ochiya; Hiroaki Kajiyama; Yusuke Yamamoto
Journal:  Cancer Sci       Date:  2021-10-19       Impact factor: 6.716

4.  Tumor-suppressor miRNA-27b-5p regulates the growth and metastatic behaviors of ovarian carcinoma cells by targeting CXCL1.

Authors:  Chun Hua Liu; Xue Ning Jing; Xiao Lan Liu; Shan Yong Qin; Min Wei Liu; Chun Hong Hou
Journal:  J Ovarian Res       Date:  2020-08-11       Impact factor: 4.234

Review 5.  The clinical impact of intra- and extracellular miRNAs in ovarian cancer.

Authors:  Kosuke Yoshida; Akira Yokoi; Tomoyasu Kato; Takahiro Ochiya; Yusuke Yamamoto
Journal:  Cancer Sci       Date:  2020-08-27       Impact factor: 6.716

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.